Fundraising Fox
/Companies
Sign in

Artica Therapeutics

Founded 2020 · 19 employees on LinkedIn · 7 known investors

Find your way into Artica Therapeutics

Sign up to see every warm intro you have to Artica Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Artica Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Artica Therapeutics develops orally bioavailable small molecule inhibitors that use covalent chemistry to achieve antibody-like efficacy, positioned as an "antibody-in-a-pill" approach. The company targets severe autoimmune and inflammatory disorders for patients with immune-mediated conditions.

BiotechDeep TechHealthtech

Founders & leadership

Artica Therapeutics was founded in 2020 by Tjeerd Barf, Arwin Ridder, and Ad IJzerman.

TBTjeerd Barf
Tjeerd BarfCo-founder & CEOTjeerd Barf brings over 25 years of pharmaceutical research and development experience across startup and large-cap organizations, with expertise in metabolic disease, immunology, and oncology. He specializes in covalent chemistry drug discovery, medicinal chemistry, and structure-based drug design for kinase and protease targets.
ARArwin Ridder
Arwin RidderCo-founder & COOArwin Ridder is co-founder and COO of Artica Therapeutics, which develops small molecule inhibitors for autoimmune and inflammatory conditions. He has worked as a drug developer and project leader on complex pharmaceutical programs.
AI
Ad IJzermanCo-founder & SAB Chair
JJason
JasonChief Scientific OfficerJason has held senior leadership positions in life sciences for over 30 years, with expertise spanning drug discovery, development, and clinical advancement across immunology, oncology, and neuroscience. He has directed multidisciplinary teams from target validation through Phase 2 clinical development and has experience in medical device development and venture capital.

Investors · 7

Thuja Capital✓ confirmed by Artica TherapeuticsUtrecht

How we know: the company's own site · funding news · biogenerationventures.com · open dataset · 5k.vc investor directory · Not right? Tell us

Seroba Life Scienceslisted by Seroba Life SciencesDublin · $540K – $7.6M

How we know: a partner's Signal profile · Not right? Tell us

BGVreportedSilicon Valley

How we know: biogenerationventures.com · Not right? Tell us

Also in the syndicate · 3

Innovation QuarterInnovationQuarterSerobalead

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does Artica Therapeutics do?
Artica Therapeutics develops orally bioavailable small molecule inhibitors that use covalent chemistry to achieve antibody-like efficacy, positioned as an "antibody-in-a-pill" approach. The company targets severe autoimmune and inflammatory disorders for patients with immune-mediated conditions.
Who founded Artica Therapeutics?
Artica Therapeutics was founded by Tjeerd Barf, Arwin Ridder, Ad IJzerman in 2020.
Who are Artica Therapeutics's investors?
Artica Therapeutics's investors include BioGeneration Ventures, Thuja Capital, Seroba Life Sciences, BGV.